Purvalanol BA cyclin-dependent kinase inhibitor

Purvalanol B (CAS 212844-54-7)

Purvalanol B | CAS 212844-54-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_17, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_361300, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 92ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: NG 95
Application: A cyclin-dependent kinase inhibitor
CAS Number: 212844-54-7
Molecular Weight: 432.90
Molecular Formula: C20H25ClN6O3
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Purvalanol B has been shown to be a Cdk (cyclin-dependent kinase) inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. This compound has also been shown to have antiproliferative properties, mediated by p42/p44 MAPK. Purvalanol B is an inhibitor of Cdk6 and Cdk9.

Physical State :
Solid
Solubility :
Soluble in DMSO (37 mg/ml), and 1eq. NaOH (100 mM). Insoluble in water.
Storage :
Store at -20° C
Melting Point :
282.24° C (Predicted)
Boiling Point :
660.60° C at 760 mmHg (Predicted)
Density :
1.44 g/cm3 (Predicted)
Refractive Index :
n20D 1.67 (Predicted)
IC50 :
Cdk2/cyclin A: IC50 = 6 nM (human); Cdk1: IC50 = 6 nM (human); Cdc2 p34/cyclin B: IC50 = 6 nM (human); Cdk5: IC50 = 6 nM (human); Cdk2/cyclin E: IC50 = 9 nM (human)
pK Values :
pKa: 2.81 (Predicted), pKb: 4.33 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
DG5056865
PubChem CID :
448991
MDL Number :
MFCD04118312
Beilstein Registry :
8653450
SMILES :
CC(C)[C@H](CO)NC1=NC2=C(C(=N1)NC3=CC(=C(C=C3)C(=O)O)Cl)N=CN2C(C)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 80ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Bullard et al Bullard et al. (PubMed ID 25879664) found that the kinase inhibitor, purvalanol B, reduced the ability of P. falciparum to form multinucleated schizonts and up-regulates proteasome subunits and proteins that contribute to redox homeostasis. -SCBT Publication Review
Date published: 2015-06-23
  • y_2019, m_11, d_17, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_361300, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 32ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.